Study of Antidepressant Efficacy of a Selective, High Affinity Enkephalinergic Agonist in Anxious Major Depressive Disorder (AMDD)

Completed · Phase 2 · Has a placebo group

Conditions studied: Anxious Major Depressive Disorder

In brief

This study will determine if a highly selective enkephalinergic receptor modulator is effective in the treatment of anxious major depressive disorder.

Key facts

Study ID

NCT00759395

Run by

AstraZeneca

People needed

22

Starts

2009-01-01

Expected to finish

2011-10-01

Last updated by the study team

2012-11-08

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Provision of informed consent prior to any study specific procedures
• Diagnosis of major depressive disorder without psychotic features (MDD)

You may not qualify if…

• A history of substance or alcohol abuse within the past 6 months or dependence within 1 year of enrollment as defined by DSM-IV criteria.
• Women that are pregnant or lactating
• History of pancreatitis

Where it is running

• Research Site — Baltimore, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.